Publication | Closed Access

The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial

Breast OncologyErbb2+ ClusterMedicinePathologyCancer GenomicsBreast CancerIntrinsic GeneCancer GeneticsCancer TreatmentOncologyRadiation OncologyTumor BiologyNeoadjuvant Chemotherapy